Zobrazeno 1 - 10
of 21
pro vyhledávání: ''
Autor:
Sze Huey Tan, Jibin Li, Mei Lin, Rui You, Guo-Ping Shen, Yi-Shan Wu, Yi-Jun Hua, Rou Jiang, Lin-Quan Tang, Ming-Yuan Chen, Rui Sun, Yu-Long Xie, Li Ling, Yong Chen, Yu-Xiang He, You-Ping Liu, Qiu-Yan Chen, Xiong Zou, Hong-Dan Zhang, Qing Liu, Jing-Yu Cao, Meng-Xia Zhang, Chong-Yang Duan, Melvin L.K. Chua, Yi-Nuan Zhang, Zhi-Qiang Wang, Ai-Hua Zhuang, Pei Yu Huang, Qi Yang, Ling Guo, Hao-Yuan Mo, Hai-Qiang Mai
Publikováno v:
JAMA Oncology. 6:1345
Importance The role of locoregional radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma (mNPC) is unclear. Objective To investigate the efficacy and safety of locoregional radiotherapy in de novo mNPC. Design, Setting, and Parti
Autor:
Linda Ahn, Maria E. Arcila, Hira Rizvi, Helena A. Yu, Glenn Heller, Michael F. Berger, Julie Li Yang, Jamie E. Chaft, Gregory J. Riely, Rachel Kim, Robert J. Young, Mark G. Kris, Alex Makhnin, Christina Falcon, Fanli Meng, Yosef Tobi, Brian Houck-Loomis, Adam J. Schoenfeld, Dana W.Y. Tsui, Marc Ladanyi, Sara A. Hayes
Publikováno v:
JAMA Oncol
IMPORTANCE: The combination of erlotinib and bevacizumab as initial treatment of epidermal growth factor receptor (EGFR [OMIM 131550])–mutant lung cancers improves progression-free survival (PFS) compared with erlotinib alone. Because osimertinib p
Autor:
Martin Sökler, Ulrich Keller, Carsten Kobe, Bastian von Tresckow, Andreas Rosenwald, Stephan Mathas, Paul J Bröckelmann, Michael Fuchs, Jasmin Mettler, Julia Meissner, Peter Borchmann, Andrea Kerkhoff, Andreas Zimmermann, Stephanie Sasse, Wolfram Klapper, Helen Goergen, Rainer Ordemann, Andreas Engert, Matthias Bormann, Teresa V Halbsguth, Christian Baues, Andreas Hüttmann
Publikováno v:
JAMA Oncol
Importance In early-stage unfavorable classic Hodgkin lymphoma (cHL), conventional therapy induces high cure rates but also relevant acute and long-term toxic effects. Nivolumab is well tolerated and highly effective in relapsed/refractory cHL but ha
Autor:
Bruce Colwell, John R. Goffin, Hagen F. Kennecke, B. Samson, Félix Couture, Setareh Samimi, Tahir Abbas, Francine Aubin, Scott R. Berry, Alice C. Wei, Dongsheng Tu, Sheryl Koski, Nadine M Magoski, Petr Kavan, Chaudhary E. Ahmad, Jonathan M. Loree, Mohammed Harb, Christopher J. O'Callaghan, Nathalie Aucoin, Eric Chen, Derek J. Jonker
Publikováno v:
JAMA Oncology. 6:831
Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are microsatellite-instability high (MSI-H).To evaluate whether combining programmed death-ligand 1 (P
Autor:
Feliciano Barrón, Miguel-Ángel Salinas Padilla, Masao Yamamoto Ramos, Andrés F. Cardona, Graciela Cruz-Rico, Pedro Barrios-Bernal, Oscar Arrieta, Laura Alejandra Ramírez-Tirado, Rafael Rosell, Manuel Jiménez, Zyanya Lucia Zatarain-Barrón, Edgar Vergara, Alejandro Avilés-Salas, Norma Hernández-Pedro
Publikováno v:
JAMA Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
JAMA Oncol
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
JAMA Oncol
Importance Metformin hydrochloride is emerging as a repurposed anticancer drug. Preclinical and retrospective studies have shown that it improves outcomes across a wide variety of neoplasms, including lung cancer. Particularly, evidence is accumulati
Autor:
Jin Seok Ahn, N. Al-Sakaff, Xavier Pivot, Roberto Hegg, Daniil Stroyakovskiy, Christian Jackisch, Dominik Heinzmann, Bohuslav Melichar, Shin-Cheh Chen, Christoph Meyenberg
Publikováno v:
JAMA Oncology. 5:e190339
IMPORTANCE: Confirmation of long-term comparability between subcutaneous and intravenous trastuzumab is essential. OBJECTIVE: To evaluate efficacy and safety of subcutaneous trastuzumab compared with that of intravenous trastuzumab for patients with
Autor:
Chiara Cremolini, Francesca Bergamo, Daniele Santini, Francesca Pucci, Gianluca Masi, Eleonora Rofi, Romano Danesi, C. Barbara, Domenico Corsi, Marzia Del Re, Elena Conca, Sara Lonardi, Emanuela Dell'Aquila, Giuseppe Aprile, Adele Busico, Carlo Barone, Nicoletta Pella, Emiliano Tamburini, Filippo Pietrantonio, Francesco Pantano, Daniele Rossini, Alfredo Falcone
Publikováno v:
JAMA Oncology. 5:343
IMPORTANCE: Based on a small retrospective study, rechallenge with cetuximab-based therapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC) who were previously treated with the same anti–epidermal growth factor receptor–based
Autor:
Thierry Conroy, Eric Francois, Gael Deplanque, François Ghiringhelli, Christian Borel, Sandrine Hiret, Jean-François Seitz, Olivier Bouché, Trevor Stanbury, Jaafar Bennouna, Antoine Adenis, Aurélie Bertaut, Marc G. Denis, Mohamed Hebbar, Christophe Borg, Pascal Artru, Gaetan Des Guetz
Publikováno v:
JAMA Oncology. 5:83
IMPORTANCE: Second-line treatment with chemotherapy plus bevacizumab or cetuximab is a valid option for metastatic colorectal cancer. OBJECTIVE: To evaluate the progression-free survival (PFS) rate at 4 months with chemotherapy plus bevacizumab vs ce
Publikováno v:
JAMA Network Open. 1:e180416
Importance Based on efficacy results from pivotal randomized clinical trials, PD-1 (programmed cell death 1) inhibitors, such as nivolumab and pembrolizumab, have been approved to treat various cancers. Response patterns with varying effects on progr
Autor:
Linda Van Le, Parviz Hanjani, Heather A. Lankes, Xun C. Zhou, Anil K. Sood, Wei Hu, Lisa M. Landrum, Carol Aghajanian, Debra L. Richardson, Angeles Alvarez Secord, Michael E. Carney, Siobhan M. Kehoe, Robert L. Coleman, Michael W. Sill, Michael L. Pearl, Heidi J. Gray
Publikováno v:
JAMA Oncology. 4:196
Importance Ovarian cancer is the leading cause of gynecologic cancer deaths in the United States. Pazopanib is an oral, multitarget kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptors